



www.eortccltf2019.com

EORTC CLTF 2019



“Insights in research and patient care”

26-28
September
Zappeion
Megaron

ATHENS
GREECE

Scientific Programme

Organized by



Under the Auspices of



Scientific / Secretariat
Support



Financial Management
/ Logistics



Programme at a Glance

Thursday, 26th September 2019

MEETING HALL 2

07:45 - 09:45 **EORTC Board Meeting** (Closed Meeting)

09:45 - 10:45 **ISCL 4WCCL Scientific Planning Committee** (Closed Meeting)

10:45 - 12:30 **EORTC Trials • PARCT • MOGA** (Investigators Meeting)

MEETING HALL 11/12

12:30 - 12:45 **CONGRESS OPENING**

12:45 - 13:45 **LUNCH SYMPOSIUM**

13:45 - 15:15 **Session 1: Biologic Insights I**

Chairs: Chalid Assaf, Germany - Martine Bagot, France - Annamari Ranki, Finland

15:15 - 16:00

Guest Lecture: New insights into the immunobiology of CTCL

Prof. Rachael A. Clark, USA

16:00 - 16:30

COFFEE BREAK

16:30 - 17:45

Session 2: PROCLIFI analysis

Chairs: Julia Scarisbrick, UK - Pietro Quaglino, Italy

17:45 - 19:15

Session 3: Biologic Insights II

Chairs: Jan Nicolay, Germany - Pablo Luis Ortiz Romero, Spain - Christina Piperi, Greece

MEETING HALL 2

19:15 - 20:15 **Young Investigator E-poster walk**

MEETING HALL 11/12

20:15 - 20:45 **OPENING CEREMONY**

20:45 **WELCOME RECEPTION**

Friday, 27th September 2019

MEETING HALL 11/12

08:00 - 09:00 **BREAKFAST SYMPOSIUM**

09:00 - 10:30

Session 4: Biologic Insights III

Chairs: Maarten Vermeer, The Netherlands - Evangelia Papadavid, Greece - Emilia Hodak, Israel

10:30 - 11:00

COFFEE BREAK

11:00 - 12:30

Session 5: Biologic Insights IV

Chairs: Marie Beylot-Barry, France - Pietro Quaglino, Italy - Emmanuella Guenova, Switzerland



Programme at a Glance

Friday, 27th September 2019

MEETING HALL 11/12

12:30 - 13:30	LUNCH SYMPOSIUM
13:30 - 15:30	Session 6: Histopathology <i>Chairs: Maxime Battistella, France - Rein Willemze, The Netherlands - Leonidas Marinou, Greece</i>
15:30 - 16:15	Session 7: Quality of life <i>Chairs: Constanze Jonak, Austria - Julia Scarisbrick, UK - Konstantinos Krasagakis, Greece</i>
16:15 - 16:45	COFFEE BREAK
16:45 - 18:00	Session 8: Treatment I <i>Chairs: Rudolf Stadler, Germany - Vasiliki Pappa, Greece - Richard Cowan, UK</i>
18:00 - 18:45	Guest Lecture: A Four Decade Journey Investigating CTCL <i>Prof. Steven T. Rosen, USA</i>
18:45 - 19:45	EORTC CLTF General Assembly Trials Update (EORTC Members only)
20:30	CONGRESS DINNER

Saturday, 28th September 2019

MEETING HALL 11/12

09:00 - 10:00	Session 9: Biologics/Psoriasis and CTCL <i>Chairs: Dimitris Ioannidis, Greece - Vasiliki Nikolaou, Greece - Ulrike Wehkamp, Germany</i>
10:00 - 10:30	Guest Lecture: Precision and Personalized medicine in cancer <i>Prof. Meletios - Athanasios Dimopoulos, Greece</i> <i>Chairs: Dimitris Rigopoulos, Greece - Alexander Stratigos, Greece - Evangelia Papadavid, Greece</i>
10:30 - 11:00	COFFEE BREAK
11:00 - 12:30	Session 10: Treatment II <i>Chairs: Ramon Pujol, Spain - Franz Trautinger, Austria - Maria Angelopoulou, Greece</i>
12:30 - 13:30	LUNCH SYMPOSIUM
13:30 - 14:30	Session 11: Treatment III <i>Chairs: Robert Knobler, Austria - Antonio Cozzio, Switzerland - Panagiotis Tsirigotis, Greece - Stephen Lloyd Morris, UK</i>
14:30 - 14:45	E-Poster Awards, Young Investigator Award <i>Chairs: Emmanuela Guenova, Switzerland - Julia Scarisbrick, UK - Evangelia Papadavid, Greece</i>
14:45 - 15:00	Outlook EORTC CLTF meeting 2019 and Meeting Closure
15:00 - 16:00	Greek Patients Meeting <i>Susan Thornton, CLF, USA</i> <i>Specialists: Evangelia Papadavid, Vasiliki Nikolaou, Vassilis Kouloulis, Panagiotis Tsirigotis et al.</i>

Scientific Programme

Thursday, 26th September 2019

09:30 - 12:30 **Registrations**

MEETING HALL 2

07:45 - 09:45 **EORTC Board Meeting** (Closed Meeting)

09:45 - 10:45 **ISCL 4WCCL Scientific Planning Committee** (Closed Meeting)

10:45 - 12:30 **EORTC Trials**
 • PARCT
 • MOGA
 (Investigators Meeting)

MEETING HALL 11/12

12:30 - 12:45 **CONGRESS OPENING**

12:45 - 13:45 **LUNCH SYMPOSIUM**

13:45 - 15:15 **Session 1: Biologic Insights I**
Chairs: Chalid Assaf, Germany - Martine Bagot, France - Annamari Ranki, Finland

PD-1 overexpression in Sézary syndrome is epigenetically regulated

Safa Najidh - abstract number 003

In Vitro Effect of Jak and HDAC Inhibitors in Cutaneous T-cell Lymphoma

Fani Karagianni - abstract number 010

Analysis of Sézary syndrome (SS) and lymphocytic variant of hypereosinophilic syndrome (L-HES) transcriptome identify common genes to reflect similar manifestation and highlight genes important in proliferation

Henry Wong - abstract number 014

Single-cell RNA sequencing with TCR repertoire profiling of mycosis fungoides

Duncan Murray - abstract number 018

A diagnostic two gene classifier in patients with Mycosis fungoides: a retrospective multicenter study

Nielsen Pia Rude - abstract number 029

Evaluation of blood Sézary markers by means of correlation with apoptosis resistance and clonality

Jan P. Nicolay - abstract number 002

Cancer-associated fibroblasts: characterization and role in mycosis fungoides lesions

Moyal Lilach - abstract number 030

Single-Cell Lymphocyte Heterogeneity in Advanced Cutaneous T-cell Lymphoma

Larisa Geskin - abstract number 031

Cutaneous T-cell lymphoma cells release proapoptotic Fas ligand in lysosomal secretory vesicles

Adèle De Masson - abstract number 048

Scientific Programme

Thursday, 26th September 2019

15:15 - 16:00

Guest Lecture: New insights into the immunobiology of CTCL

Prof. Rachael A. Clark, USA

16:00 - 16:30

COFFEE BREAK

16:30 - 17:45

Session 2: PROCLIPI analysis

Chairs: Julia Scarisbrick, UK - Pietro Quaglino, Italy

T-cell receptor (TCR) rearrangements in the skin and blood of patients in the PROCLIPI study: Detection of clonal rearrangements in the skin (and blood) correlates with the B-class of MF and SS patients

Ulrike Wehkamp - abstract number 070

Lymph Node Imaging and Correlation with Histological N-class; Results from the PROCLIPI Study show sum of the product of dimensions is the better predictor than single axis measurements

Jinah Yoo - abstract number 071

Prognostic Factors in Mycosis Fungoides: The PROCLIPI Study

Julia Scarisbrick - abstract number 072

An International Multi-Institutional Study for the Evaluation of Folliculotropic Mycosis Fungoides - Results of the Consensus Histopathologic Review

Alejandro A. Gru - abstract number 073

Treatment of Early-Phase Mycosis Fungoides: Results from the PROspective Cutaneous Lymphoma International Study (PROCLIPI study)

Pietro Quaglino - abstract number 074

Folliculotropic mycosis fungoides presents with 2 distinct clinicopathological presentations: an international virtual study

Emmilia Hodak - abstract number 075

17:45 - 19:15

Session 3: Biologic Insights II

Chairs: Jan Nicolay, Germany - Pablo Luis Ortiz Romero, Spain - Christina Piperi, Greece

Molecular analysis of primary cutaneous diffuse large B-cell lymphoma, leg type at diagnosis and relapse

Anne-Roos Schrader - abstract number 022

Whole-genome analysis uncovers recurrent IKZF1 inactivation and aberrant cell adhesion in blastic plasmacytoid dendritic cell neoplasm

Armando Bastidas Torres - abstract number 023

Cell adhesion molecule 1 (CADM1) can be a biomarker for Sézary syndrome

Yuki Nakagawa - abstract number 019

Importance of circulating miRNAs in CTCL diagnosis

Konstantina Saraki, Marianna Papadaki - abstract number 032

Scientific Programme

Thursday, 26th September 2019

Antibiotics inhibit tumor and disease activity in cutaneous T cell lymphoma

Lise M. Lindahl - abstract number 013

A malignant PLCG1-PRKCQ-STAT3 signalling axis controlling tumorigenesis and progression of Cutaneous T-cell Lymphomas

Jose Pedro Vaqué - abstract number 017

Circulating tumor cells in mycosis fungoides patients detected by next generation sequencing of T-cell-receptor gene rearrangements and correlation with clinical stage

Ulrike Wehkamp - abstract number 001

The Role of the Extracellular Matrix in Promoting Early Stage Mycosis Fungoides

Neda Nikbakht - abstract number 006

MEETING HALL 2

19:15 - 20:15 **Young Investigator E-poster walk**

MEETING HALL 11/12

20:15 - 20:45 **OPENING CEREMONY**

20:45 **WELCOME RECEPTION**

Scientific Programme

Friday, 27th September 2019

MEETING HALL 11/12

08:00 - 09:00 **BREAKFAST SYMPOSIUM**

09:00 - 10:30 **Session 4: Biologic Insights III**

Chairs: Maarten Vermeer, The Netherlands - Evangelia Papadavid, Greece - Emilia Hodak, Israel

Malignant, benign conventional and regulatory T immune compartments in 36 patients treated with mogamulizumab for advanced CTCL

Marie Roelens - abstract number 012

Resminostat increases NK cell-mediated lysis of malignant cells beneficially affecting the function of opsonizing antibodies

Matthias Borgmann - abstract number 007

Clinician-level variation in mechlorethamine treatment duration in mycosis fungoides cutaneous T-cell lymphoma (MF-CTCL)

Christiane Querfeld - abstract number 021

Transcriptional impact of resminostat and other HDAC inhibitors on disease-related gene expression in CTCL

Gundula Streubel - abstract number 027

Long-term clinical outcome and HAVCR2 mutations in 70 patients with subcutaneous panniculitis-like T-cell lymphoma: a study from the French Cutaneous Lymphoma Group

Adèle De Masson - abstract number 020

Clinical aspects and outcome of lymphoblastic leukemia/lymphoma with cutaneous involvement

Maxime Battistella - abstract number 028

A retrospective analysis of patients with co-existent mycosis fungoides and primary cutaneous anaplastic large cell lymphoma from the Australian Cutaneous Lymphoma Network database

Crystal Gao - abstract number 011

Defining B2 involvement in Sezary Syndrome results from the PROCLIFI study

Manrup Hunjan - abstract number 016

10:30 - 11:00 **COFFEE BREAK**

11:00 - 12:30 **Session 5: Biologic Insights IV**

Chairs: Marie Beylot - Barry, France - Pietro Quaglino, Italy - Emmanuela Guenova, Switzerland

Risk of cardiovascular events in patients with cutaneous T-cell lymphomas

Courtney Johnson - abstract number 015

Peripheral T cell lymphoma, not otherwise specified involving the skin: is it always aggressive?

Jade Cury-Martins - abstract number 009

Scientific Programme

Friday, 27th September 2019

Demodex-induced follicular mucinosis of the head and neck mimicking folliculotropic mycosis fungoides

Megan H. Trager - abstract number 026

Outcomes and prognostic factors in African American / black patients with mycosis fungoides and Sézary syndrome

Shamir Geller - abstract number 024

Mycosis fungoides is associated with melanoma in Israeli patients

Shany Sherman - abstract number 025

Extranodal NK/T-cell lymphoma, nasal type in a Brazilian tertiary center

Denis Miyashiro - abstract number 004

Blastic plasmacytoid dendritic cell neoplasm: a series of fourteen cases from a reference center in Brazil

Jade Cury-Martins - abstract number 008

Expression of programmed death-1 (PD-1) and its ligands in Sézary syndrome

Emmanuella Guenova - abstract number 033

12:30 - 13:30

LUNCH SYMPOSIUM

13:30 - 15:30

Session 6: Histopathology

Chairs: Maxime Battistella, France - Rein Willemze, The Netherlands - Leonidas Marinou, Greece

Clinical, histological and molecular characteristics of ALK-positive primary cutaneous anaplastic large cell lymphoma

Rutger Melchers - abstract number 050

CD30 expression in rare cutaneous lymphomas

Ulrike Wehkamp - abstract number 051

Prognostic value of histopathologic features in folliculotropic mycosis fungoides presenting with plaques

Suzanne Van Santen - abstract number 052

Lymphomatoid papulosis types D and E: a multicentric series on 21 patients.

Nicolas Ortonne - abstract number 053

Pityriasis lichenoides: relevance of the current classification?

Nicolas Ortonne - abstract number 054

Primary cutaneous large B-cell lymphomas: relevance of the 2017 World Health Organization classification: clinicopathological and molecular analyses of 64 cases

Sarah Menguy - abstract number 055

Double-hit and dual expression of MYC and BCL2 in primary cutaneous large B-cell lymphomas

Sarah Menguy - abstract number 056



Scientific Programme

Friday, 27th September 2019

Indolent gamma delta positive indolent cutaneous T-cell lymphoma: two cases and review of the literature

J.M. Junkins-Hopkins - abstract number 057

N3 status in mycosis fungoides and Sézary syndrome is associated with a poor prognosis at first diagnosis and disease progression

Bethanie Rooke - abstract number 058

Altered expression of inflammasome on the skin and lymph nodes in sézary syndrome

Denis Miyashiro - abstract number 059

Histopathology of Cutaneous Infiltrates in Patients With MDS

Syed M. Hasan Rizvi - abstract number 060

Lymphomatoid papulosis type E with subcutaneous tissue infiltration and prominent rimming

Fina Climent - abstract number 061

15:30 - 16:15

Session 7: Quality of life

Chairs: Constanze Jonak, Austria - Julia Scarisbrick, UK - Konstantinos Krasagakis, Greece

Cutaneous T-cell lymphoma and second cancer: a two - centre experience

Alessandro Pileri - abstract number 105

HDACi resminostat causes a sustained reduction of the pruritus mediator IL-31 in CTCL cells

Gundula Streubel - abstract number 106

An overall response in skin is associated with improved HRQoL in patients with MF/SS enrolled in the PROCLIFI study

Kevin Molloy - abstract number 107

Efficacy and quality of life (QoL) in patients with mycosis fungoides cutaneous T-cell lymphoma (MF-CTCL) treated with chlormethine gel and other therapies: Results from the PROVe study

Ellen Kim - abstract number 108

16:15 - 16:45

COFFEE BREAK

16:45 - 18:00

Session 8: Treatment I

Chairs: Rudolf Stadler, Germany - Vasiliki Pappa, Greece - Richard Cowan, UK

Efficacy of chlormethine gel in patients with stage I-IIA mycosis fungoides cutaneous T-cell lymphoma (MF-CTCL): Re-analysis of a randomized phase 2 study

Larisa Geskin - abstract number 082

Low-Dose Gemcitabine Therapy in CTCL - "Real-life" Data of the German Cutaneous Lymphoma Network

Christoph Blazejak - abstract number 084

Scientific Programme

Friday, 27th September 2019

Anti-CD7 immunotherapy is mediated by cytotoxic CD107a+IFN- γ - NK cells and can be potentiated by interferon- α in cutaneous lymphoma

Oleg Akilov - abstract number 090

Real life data on advanced cutaneous T cell lymphoma patients treated with brentuximab vedotin: results from a multicentre European EORTC study

Eirini Kapniari - abstract number 094

Brentuximab vedotin (BV) versus physician's choice (PC) of methotrexate or bexarotene in adult patients with previously treated CD30-positive cutaneous T-cell lymphoma (CTCL; mycosis fungoides [MF] or primary cutaneous anaplastic large cell lymphoma [pcALCL]): final time to next therapy (TTNT) results from the phase 3 ALCANZA study

Julia Scarisbrick - abstract number 085

A multicentre, double blind, randomised, placebo controlled, phase II trial to evaluate resminostat for maintenance treatment of patients with advanced stage (stage IIB IVB) mycosis fungoides (MF) or Sézary Syndrome (SS) that have achieved disease control with systemic therapy - the RESMAIN study

Rudolf Stadler - abstract number 088

18:00 - 18:45

Guest Lecture: A Four Decade Journey Investigating CTCL

Prof. Steven T. Rosen, USA

18:45 - 19:45

EORTC CLTF General Assembly Trials Update (EORTC Members only)

20:30

CONGRESS DINNER

Scientific Programme

Saturday, 28th September 2019

MEETING HALL 11/12

09:00 - 10:00

Session 9: Biologics/Psoriasis and CTCL

Chairs: Dimitris Ioannidis, Greece - Vasiliki Nikolaou, Greece - Ulrike Wehkamp, Germany

Cutaneous lymphomas behaves worse in patients treated with biologics for psoriasis: a multicenter study

Vasiliki Nikolaou - abstract number 113

PD-L1 is regulated by proinflammatory cytokines in cutaneous T cell lymphoma

Christiane Querfeld - abstract number 114

Three cases of new diagnosis of mycosis fungoides following commencement on biologic therapies for presumed psoriasis/eczema

Jinah Yoo - abstract number 115

Blocking TNF- α /Th17 Pathway with Monoclonal Cytokine Antibodies May Aggravate the Course of Mycosis Fungoides - A Multicenter Retrospective Analysis of Real-World Clinical Data

Iris Amitay-Laish - abstract number 116

10:00 - 10:30

Guest Lecture: Precision and Personalized medicine in cancer

Prof. Meletios - Athanasios Dimopoulos

Chairs: Dimitris Rigopoulos, Greece - Alexander Stratigos, Greece - Evangelia Papadavid, Greece

10:30 - 11:00

COFFEE BREAK

11:00 - 12:30

Session 10: Treatment II

Chairs: Ramon Pujol, Spain - Franz Trautinger, Austria - Maria Angelopoulou, Greece

Demyelinating motor neuropathy of the median nerve following brentuximab vedotin extravasate

Christina Mitteldorf - abstract number 089

Treatment of rare patients with a primary cutaneous CD30+ lymphoproliferation developing extracutaneous disease: a retrospective study of 43 patients

Rutger Melchers - abstract number 078

The combination of brentuximab-vedotin with skin-directed therapies in response to PD extend the time to the next therapeutic line

René Stranzenbach - abstract number 091

A Phase II Trial of Brentuximab vedotin (BV) and lenalidomide (Len) in relapsed and refractory (r/r) cutaneous (CTCL) and peripheral (PTCL) T-cell lymphomas

Joseph Maakaron - abstract number 077

Treatment of mycosis fungoides/Sezary syndrome with brentuximab vedotin on the compassionate use programme and CDF: outcomes and toxicities

Sam Enefer - abstract number 079

Scientific Programme

Saturday, 28th September 2019

Response to topical corticosteroid monotherapy in mycosis fungoides

Saritha Kartan - abstract number 083

SOLAR: A Phase 2, Global, Randomized, Active Comparator Study to Investigate the Efficacy and Safety of Cobomarsen in Subjects with Mycosis Fungoides (MF)

Julia Scarisbrick - abstract number 087

Clinical diversity and treatment approaches to blastic plasmacytoid dendritic cell neoplasm: a retrospective multicentre study

Emmanuella Guenova - abstract number 092

12:30 - 13:30

LUNCH SYMPOSIUM

13:30 - 14:30

Session 11: Treatment III

Chairs: Robert Knobler, Austria - Antonio Cozzio, Switzerland - Panagiotis Tsirigotis, Greece - Stephen Lloyd Morris, UK

Allogeneic hematopoietic stem cell transplantation for the treatment of patients with refractory Mycosis Fungoides/Sezary Syndrome: A single center experience

Panagiotis Tsirigotis - abstract number 093

Long-term disease control after stem cell transplantation in primary cutaneous T-cell lymphoma: a single-center analysis

Florentia Dimitriou - abstract number 095

A review of 65 patients with mycosis fungoides/Sezary syndrome treated with extracorporeal photopheresis: our experience at Peter MacCallum Cancer Centre

Crystal Gao - abstract number 080

Efficacy of Mogamulizumab in Previously Treated Patients With Less Advanced Mycosis Fungoides (MF): Results From the MAVORIC Study

Julia Scarisbrick - abstract number 086

Evaluation of haematopoietic stem cell transplantation in patients diagnosed with cutaneous T cell lymphoma using reduced conditioning regime with total skin electron beam, total nodal irradiation and anti-thymocyte globulin

Ritchie Sebastian - abstract number 081

14:30 - 14:45

E-Poster Awards, Young Investigator Award

Chairs: Emmanuella Guenova, Switzerland - Julia Scarisbrick, UK - Evangelia Papadavid, Greece

14:45 - 15:00

Outlook EORTC CLTF meeting 2019 and Meeting Closure

15:00 - 16:00

Greek Patients Meeting

Susan Thornton, CLF, USA

Specialists: Evangelia Papadavid, Vasiliki Nikolaou, Vassilis Kouloulis, Panagiotis Tsirigotis et al.



E-Poster Exhibition

MEETING HALL 2

abstract No. Title

- 034** The diagnostic and prognostic value of five blood markers in cutaneous T-cell lymphomas: a validation cohort
- 039** Genetic alterations in CD30-positive lymphoproliferations
- 036** Primary cutaneous marginal zone lymphoma: relevance of searching for a blood B-cell clone ?
- 038** Clonality assessment in blood and immunotyping of malignant cells to support choice of treatment for erythrodermic CTCL patients, a CD52 success story of precision medicine
- 049** Augmented apoptotic efficacy of Brentuximab vedotin combined with lenalidomide in CD-30 expressing Sézary Syndrome cell lines
- 035** Upregulation of Integrin-associated protein on tumor T cells in CTCL inhibits IL-12 and Th1 immunity
- 043** Sequential comprehensive molecular work-up of treatment-resistant mycosis fungoides with systemic dissemination during a 4-year period
- 037** Cutaneous T cell lymphoma mouse model used to study the therapeutic mechanisms of phototherapy
- 042** Upregulation of HLA I on tumor skin T lymphocytes as a tumor immune escape mechanism in CTCL
- 044** Effect of extracorporeal photopheresis on antibody-dependent cellular cytotoxicity in patients with Sézary-syndrome
- 046** Pityriasis lichenoides in patients with mycosis fungoides – our experience
- 047** Selection of suitable cases for random skin biopsy for the diagnosis for intravascular large B cell lymphoma
- 045** Metabolite profile of extracellular vesicles derived of a cutaneous T-cell lymphoma (CTCL) cell line
- 005** Transformed mycosis fungoides in a Brazilian tertiary center
- 040** Interleukin 1 beta derived abscesses in a patient with folliculotropic and granulomatous mycosis fungoides with large cell transformation.
- 041** Mycosis fungoides: the great mimicker
- 065** Primary cutaneous lymphoma patterns in the North-Western region of Romania
- 069** Challenges in the diagnosis of CD30+ anaplastic large - cell lymphoma
- 063** Diagnostic and Clinical Significance of Eccrinotropism in Mycosis Fungoides
- 068** Infection with human T-cell lymphotropic virus type-1 in primary cutaneous lymphoma: Should we be testing all patients?
- 064** Large cells with Cd30 expression and Hodgkin-like features in primary cutaneous marginal zone B-cell lymphoma: A study of 13 cases
- 066** Primary cutaneous peripheral T-cell lymphoma not otherwise specified: a comparative clinicopathological analysis of 5 cases

E-Poster Exhibition

abstract No. Title

- 067** Pediatric Lymphomatoid Papulosis
- 062** Cutaneous lymphoid hyperplasia: clinical course and disease outcome in a case series
- 076** Retrospective validation of prognostic markers and models in a cohort of 60 patients with lethal mycosis fungoides
- 098** Contemporary treatment patterns and response in relapse/refractory cutaneous T-cell lymphoma (CTCL) in clinical practice in France, Germany Italy, Spain and the United Kingdom
- 099** Systemic rituximab in the treatment of indolent primary cutaneous B-cell lymphomas
- 100** Treatment of Sézary syndrome with alemtuzumab: a case series (2009-2019)
- 096** Early-stage mycosis fungoides: incidence and differential survival
- 104** Generalized doxorubicin-induced radiation recall dermatitis following total skin electron beam therapy
- 102** Selective inhibition of HDAC6 sensitizes CTCL to PI3K inhibitors
- 103** Pembrolizumab maintenance therapy after total- skin electron beam therapy (TSEBT) at erythrodermic Mycosis fungoides patient
- 097** Mycosis fungoides and variants of mycosis fungoides: A retrospective study of 93 patients in a Chinese population at a single center
- 101** CD30 and Lymphomas: The clue-for four?
- 109** Effect of oral psoralen plus UV-A (PUVA) photochemotherapy on quality of life, anxiety and depression in patients with early-stage mycosis fungoides
- 111** Quality of life in Greek patients with mycosis fungoides – a cross- sectional study
- 112** Health-related quality-of-life assessment in patients with cutaneous t-cell lymphoma and multimodality therapy
- 110** Neglected cases and quality of life
- 120** Folliculotropic mycosis fungoides in the setting of nivolumab immunotherapy
- 118** A case of mycosis fungoides with large cell transformation following dupilumab treatment
- 117** Mycosis fungoides progression in the setting of ustekinumab therapy for psoriasis: Report of two cases
- 119** The expression of CD39 on circulating Sezary cells is genetically controlled
- 122** Chronic actinic dermatitis or cutaneous T cell lymphoma?
- 123** Lymphoproliferative diseases among patients treated with biologicals. A case study and single center survey.
- 121** Rituximab, lenalidomide and pembrolizumab in refractory primary cutaneous diffuse large B cell lymphoma, leg type.



EORTC
CLTF 2019
"Insights in research and patient care"



www.eortccltf2019.com